Iberdomide - Bristol Myers Squibb
Alternative Names: BMS 986382; CC-220; IBERLatest Information Update: 26 Sep 2025
At a glance
- Originator Celgene Corporation
- Developer Bristol-Myers Squibb; Celgene Corporation; Emory University
- Class Anti-inflammatories; Antineoplastics; Isoindoles; Piperidones; Skin disorder therapies; Small molecules
- Mechanism of Action Ubiquitin protein ligase complex modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Multiple myeloma
- Phase II Smoldering multiple myeloma
- Phase I B-cell lymphoma; Lymphoma
- Discontinued Atopic dermatitis; Cutaneous lupus erythematosus; Follicular lymphoma; Sarcoidosis; Systemic lupus erythematosus; Systemic scleroderma
Most Recent Events
- 23 Sep 2025 Interim efficacy and adverse events data from the phase III EXCALIBER-RRMM trial in multiple myeloma released by Bristol-Myers Squibb
- 28 Jul 2025 Celegen corporation initiates phase-I clinical trials in Multiple myeloma (Combination therapy, Second-line therapy or greater) in USA (PO) (NCT06348108)
- 12 Jun 2025 Updated efficacy and adverse events data from the phase Ib/IIa CC-220-MM-001 trial in Multiple myeloma released by Bristol-Myers Squibb